CAMBRIDGE, Mass., Sept. 21 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced that Richard
T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview
and update the Company's oncology pipeline on Thursday, September 29th at
12:30 pm at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel
in New York City.
About Xanthus
Xanthus is an oncology drug development company. Xanthus' small molecule
candidates are Xanafide(TM), Symadex(TM) and Clomet(TM) which are advancing in
clinical and preclinical development for multiple cancer indications. Each of
these product candidates was in-licensed based on significant clinical and/or
preclinical data supporting safety and activity. Xanthus also has proprietary
technology to individualize patient dosing, which it believes may help improve
the performance of certain drugs in development, and facilitate the life cycle
management of certain marketed products, without limiting patient populations
or markets.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. --
kwatson@macbiocom.com or (508) 647-0209
Richard T. Dean, Ph.D., Chief Executive Officer, Xanthus Life Sciences --
(617) 225-0522
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
Richard T. Dean, Ph.D., Chief Executive Officer, of Xanthus Life
Sciences, +1-617-225-0522
|
